Ramucirumab + Paclitaxel
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Squamous Cell Carcinoma of the Esophagus
Conditions
Squamous Cell Carcinoma of the Esophagus
Trial Timeline
Mar 8, 2019 → Nov 25, 2022
NCT ID
NCT03762564About Ramucirumab + Paclitaxel
Ramucirumab + Paclitaxel is a phase 2 stage product being developed by Eli Lilly for Squamous Cell Carcinoma of the Esophagus. The current trial status is completed. This product is registered under clinical trial identifier NCT03762564. Target conditions include Squamous Cell Carcinoma of the Esophagus.
What happened to similar drugs?
4 of 20 similar drugs in Squamous Cell Carcinoma of the Esophagus were approved
Approved (4) Terminated (2) Active (14)
🔄Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02307812 | Pre-clinical | Completed |
| NCT03762564 | Phase 2 | Completed |
| NCT03760822 | Phase 2 | Active |
| NCT02514551 | Phase 2 | Completed |
Competing Products
20 competing products in Squamous Cell Carcinoma of the Esophagus